Alternative promoter usage generates novel shorter MAPT mRNA transcripts in Alzheimer’s disease and progressive supranuclear palsy brains. L'utilisation d'un promoteur alternatif de MAPT génère de nouveaux transcrits ARNm plus courts dans le cerveau des malades d'Alzheimer et de paralysie supranucléaire progressive

Archive ouverte

Huin, Vincent | Deramecourt, Vincent | Caparros-Lefebvre, Dominique | Maurage, Claude, Alain | Duyckaerts, Charles | Kovari, Eniko | Buée-Scherrer, Valérie | Labreuche, Julien | Pasquier, Florence | Behal, Hélène | Buée, Luc | Dhaenens, Claire-Marie | Sablonnière, Bernard

Edité par CCSD ; Nature Publishing Group -

International audience. Alternative promoter usage is an important mechanism for transcriptome diversity and the regulation of gene expression. Indeed, this alternative usage may influence tissue/subcellular specificity, protein translation and function of the proteins. The existence of an alternative promoter for MAPT gene was considered for a long time to explain differential tissue specificity and differential response to transcription and growth factors between mRNA transcripts. The alternative promoter usage could explain partly the different tau proteins expression patterns observed in tauopathies. Here, we report on our discovery of a functional alternative promoter for MAPT, located upstream of the gene's second exon (exon 1). By analyzing genome databases and brain tissue from control individuals and patients with Alzheimer's disease or progressive supranuclear palsy, we identified novel shorter transcripts derived from this alternative promoter. These transcripts are increased in patients' brain tissue as assessed by 5'RACE-PCR and qPCR. We suggest that these new MAPT isoforms can be translated into normal or amino-terminal-truncated tau proteins. We further suggest that activation of MAPT's alternative promoter under pathological conditions leads to the production of truncated proteins, changes in protein localization and function, and thus neurodegeneration.

Suggestions

Du même auteur

The MAPT gene is differentially methylated in the progressive supranuclear palsy brain. Le gène MAPT est méthylé différentiellement dans le cerveau dans la paralysie supranucléaire progressive. The MAPT gene is differentially methylated in the progressive supranuclear palsy brain: Hypomethylation of MAPT in PSP brain. Le gène MAPT est méthylé différentiellement dans le cerveau dans la paralysie supranucléaire progressive: Hypométhylation de la MAPT dans le cerveau des PSP

Archive ouverte | Huin, Vincent | CCSD

International audience. Background: Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease causing parkinsonian symptoms. Altered DNA methylation of the microtubule-associated protein tau gene corr...

A geographical cluster of progressive supranuclear palsy in northern France. Un cluster géographique de paralysie supranucléaire progressive dans le nord de la France

Archive ouverte | Caparros-Lefebvre, Dominique | CCSD

International audience. Objective: To describe a cluster of progressive supranuclear palsy (PSP) in northern France. PSP has not been reported in geographical, temporal, or occupational clusters. A unit of Neurology...

Comment les acteurs moléculaires de la pathologie Alzheimer permettent de comprendre la démence ? Quelles conséquences diagnostiques et thérapeutiques ?

Archive ouverte | Buée, Luc | CCSD

International audience

Chargement des enrichissements...